NEW YORK (GenomeWeb News) – Everist Genomics today said that it has received the US Clinical Laboratory Improvement Amendment certification required for it to launch its OncoDefender-CRC assay.
The Ann Arbor, Mich.-based firm plans to officially launch the test, which is a gene-based assay used in stage I and II colon cancer and stage I rectal cancer patients to assess the risk of recurrence following surgery, later this month.
"We expect that meeting the challenging certification guidelines enabling our clinical laboratory to perform high-complexity testing will give physicians and patients greater confidence when ordering the OncoDefender-CRC test," Prasad Sunkara, president and CEO of Everist Genomics, said in a statement.